Resilient Biotics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Mezzanine
- Latest Deal Amount
-
$1.5M
- Investors
-
9
Resilient Biotics General Information
Description
Developer of non-antibiotic, microbiome-based therapeutics designed to combat complex respiratory infections with applications in human and animal health. The company utilizes a proprietary discovery platform that incorporates high-resolution genomic analyses, in-house machine learning algorithms, and targeted in vitro assays to identify naturally occurring microbiome-derived strains that have immune activation and pathogen inhibition properties in respiratory tissues, enabling the animal and healthcare industry with more effective treatment strategies while reducing dependency on antibiotics.
Contact Information
Website
www.resilientbiotics.comCorporate Office
- 2 Davis Drive
- Durham, NC 27709
- United States
Corporate Office
- 2 Davis Drive
- Durham, NC 27709
- United States
Resilient Biotics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Mezzanine | 12-Dec-2024 | $1.5M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 18-Aug-2022 | Completed | Generating Revenue | |||
| 5. Grant | 25-Mar-2021 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series A) | 09-Dec-2020 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 25-Jul-2017 | $20K | $20K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Resilient Biotics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 10,909,702 | $0.000100 | $0.6 | $0.6 | 1x | $0.6 | 25.74% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Resilient Biotics Patents
Resilient Biotics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180137243-A1 | Therapeutic methods using metagenomic data from microbial communities | Inactive | 17-Nov-2016 |
Resilient Biotics Signals
Resilient Biotics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Beef Alliance | Corporation | |||
| Elanco Animal Health | Corporation | Minority | ||
| Fulcrum Global Capital | Venture Capital | Minority | ||
| iiM (Merriam) | Venture Capital | Minority |
Resilient Biotics FAQs
-
When was Resilient Biotics founded?
Resilient Biotics was founded in 2016.
-
Where is Resilient Biotics headquartered?
Resilient Biotics is headquartered in Durham, NC.
-
What is the size of Resilient Biotics?
Resilient Biotics has 5 total employees.
-
What industry is Resilient Biotics in?
Resilient Biotics’s primary industry is Drug Discovery.
-
Is Resilient Biotics a private or public company?
Resilient Biotics is a Private company.
-
What is Resilient Biotics’s current revenue?
The current revenue for Resilient Biotics is .
-
How much funding has Resilient Biotics raised over time?
Resilient Biotics has raised $11.1M.
-
Who are Resilient Biotics’s investors?
ARCH Venture Partners, Beef Alliance, Elanco Animal Health, Fulcrum Global Capital, and iiM (Merriam) are 5 of 9 investors who have invested in Resilient Biotics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process